60
Participants
Start Date
August 31, 2013
Primary Completion Date
August 31, 2017
Study Completion Date
August 31, 2017
Scopolamine
Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
intranasal placebo
Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
University of California, Los Angeles, Los Angeles
University of California, Los Angeles
OTHER